噻托溴铵喷雾剂治疗慢阻肺的系统评价
该系统评价纳入11项RCT,比较噻托溴铵喷雾剂与安慰剂及粉吸入剂治疗慢阻肺的疗效与安全性。结果显示喷雾剂在改善FEV1和FVC方面优于安慰剂,急性加重风险较低,疗效与粉吸入剂相似,安全性无显著差异。
要点
- 噻托溴铵喷雾剂改善FEV1和FVC优于安慰剂,与粉吸入剂疗效相似。
- 喷雾剂5μg组急性加重风险低于安慰剂,与粉吸入剂相似。
- 不良反应发生率与安慰剂及粉吸入剂无显著差异。
核心结论
- 噻托溴铵喷雾剂与粉吸入剂疗效相似,均能有效改善慢阻肺患者肺功能及临床症状,安全性较好。
- 远期疗效及安全性有待长期随访的RCT验证。
研究设计与样本
- Cochrane系统评价,检索Cochrane Library、PubMed、EMbase、CNKI、VIP、CBM和万方数据(建库至2016年1月)。
- 纳入11项RCT评价疗效,9项RCT评价不良反应发生率。
- 采用RevMan 5.3软件进行统计分析。
主要发现
- FEV1:喷雾剂与粉吸入剂相似[5μg: MD=0.00,95%CI(-0.04-0.04),P=0.94;2.5μg: MD=-0.04,95%CI(-0.10-0.01),P=0.12;10μg: MD=0.02,95%CI(-0.06-0.09),P=0.66]。
- FVC:喷雾剂组优于安慰剂组[MD=0.18,95%CI(0.09-0.28),P=0.0002];与粉吸入剂相似[2.5μg: MD=-0.06,95%CI(-0.16-0.04),P=0.24;5μg: MD=-0.00,95%CI(-0.08-0.08),P=1.00;10μg: MD=0.02,95%CI(-0.14-0.19),P=0.78]。
关键数值与推荐
- Cmax,ss:喷雾剂与粉吸入剂相似[MD=0.2,95%CI(-5.1-5.5),P=0.94]。
- AUC(0-6h,ss):喷雾剂与粉吸入剂相似[MD=-1.01,95%CI(-11.78-9.77),P=0.85]。
- 不良反应发生率:喷雾剂与粉吸入剂[RR=0.95,95%CI(0.89-1.00),P=0.05]及安慰剂[OR=1.07,95%CI(1.00-1.16),P=0.06]均无显著差异。
临床怎么用
- 噻托溴铵喷雾剂可作为慢阻肺维持治疗选择,疗效与粉吸入剂相当。
- 喷雾剂5μg可降低急性加重风险并改善生活质量。
- 长期使用仍需关注远期安全性数据。
局限性
- 远期疗效及安全性有待长期随访的高质量、大样本RCT验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease (COPD) according to the Cochrane systematic evaluation. Methods: The Cochrane Library, PubMed, EMbase, CNKI, VIP and CBM, Wanfang Data were searched(from the foundation date to Jan. 2016) for the randomized controlled trials (RCTs) of tiotropium Respimat in the treatment of patients with COPD. Two reviewers independently retrieved the RCTs according to the inclusion and exclusion criteria, assessed the methodological quality of the included trials.and performed statistical analysis on the data using RevMan 5.3 software. Results: Totally 11 RCTs on efficacy were finally included.The results of the combined analysis showed that FEV(1) was significantly improved in the tiotropium Respimat group than that in the placebo group[MD=0.12, 95%CI(0.10-0.14), P<0.000 01], while FEV(1) was similar between the tiotropium Respimat group and the tiotropium HandiHaler group[5 μg: MD=0.00, 95%CI(-0.04-0.04), P=0.94; 2.5 μg: MD=-0.04, 95%CI(-0.10-0.01), P=0.12; 10 μg: MD=0.02, 95%CI(-0.06-0.09), P=0.66]. FVC was significantly improved in the tiotropium Respimat group than that in the placebo group[MD=0.18, 95%CI(0.09-0.28), P=0.0002], while FVC was similar between the tiotropium Respimat group and the HandiHaler group[2.5 μg: MD=-0.06, 95%CI(-0.16-0.04), P=0.24; 5 μg: MD=-0.00, 95%CI(-0.08-0.08), P=1.00; 10 μg: MD=0.02, 95%CI(-0.14-0.19), P=0.78]. The risk of acute exacerbations was lower in the tiotropium Respimat group (5 μg / kg) than in the placebo group [OR=0.72, 95%CI(0.60-0.86), P=0.000 3]. It was similar in the tiotropium Respimat group (5 μg) and the HandiHaler group[OR=1.01, 95%CI(0.94-1.09), P=0.71]. The SGRQ total score of the tiotropium Respimat group (5 μg) was significantly different from that of the placebo group[MD=-3.6, 95%CI(-3.88--3.32), P<0.000 01]. C(max, ss) and AUC(0-6 h, ss) were also similar between the tiotropium Respimat group and the HandiHaler group[MD=0.2, 95%CI(-5.1-5.5), P=0.94]; MD=-1.01, 95%CI(-11.78-9.77), P=0.85]. Nine RCTs were included in the evaluation of the incident rates of adverse drug reactions(ADR). There was no significant difference between the tiotropium Respimat group HandiHaler group and the placebo group[RR=0.95, 95%CI(0.89-1.00), P=0.05], [OR=1.07, 95%CI(1.00-1.16), P=0.06]. Conclusions: The efficacy and safety of tiotropium Respimat was similar to tiotropium HandiHaler in the treatment of COPD. They can effectively improve the pulmonary function and clinical symptoms of patients. But the long-term efficacy and safety of tiotropium Respimat still need to be confirmed by higher quality and larger RCTs with long-term follow-up. 目的: 系统评价噻托溴铵喷雾剂治疗慢性阻塞性肺疾病(慢阻肺)的疗效和安全性。 方法: 以"tiotropium respimat"、"tiotropium bromide spray"、"chronic obstructive pulmonary disease"、"COPD"、"randomized"、"controlled"、"randomly"为英文检索词,"噻托溴铵喷雾剂"、"慢阻肺"、"慢性阻塞性肺疾病"、"随机对照"为中文检索词,分别检索Cochrane Library、PubMed、EMbase、中国知网、维普数据、中国生物医学文献数据库和万方数据,各数据库检索时间均从建库至2016年10月。按照Cochrane系统评价方法检索噻托溴铵喷雾剂治疗慢阻肺的所有随机对照试验(RCT),2名研究者按照纳入排除标准进行数据提取和质量评价,采用RevMan 5.3软件进行统计分析。 结果: 共纳入11个RCT研究,对文献进行不同指标分析:在改善患者FEV(1)水平方面,噻托溴铵喷雾剂组(5 μg/吸)优于安慰剂组[MD=0.12,95%CI(0.10~0.14),P<0.01]。不同剂量噻托溴铵喷雾剂组均与粉吸入剂组疗效相似[5 μg: MD=0.00,95%CI(-0.04~0.04),P=0.94;2.5 μg:MD=-0.04,95%CI(-0.10~0.01),P=0.12;10 μg:MD=0.02,95%CI(-0.06~0.09),P=0.66]。在改善患者FVC水平方面,噻托溴铵喷雾剂组(5 μg/吸)优于安慰剂组[MD=0.18,95%CI(0.09~0.28),P<0.01]。不同剂量噻托溴铵喷雾剂组与粉吸入剂组疗效相似[2.5 μg:MD=-0.06,95%CI(-0.16~0.04),P=0.24;5 μg:MD=-0.00, 95%CI(-0.08~0.08),P=1.00;10 μg:MD=0.02,95%CI(-0.14~0.19),P=0.78]。在急性加重风险方面,噻托溴铵喷雾剂组(5 μg/吸)发生急性加重的风险较安慰剂组低[OR=0.72, 95%CI(0.60~0.86),P<0.01]。噻托溴铵喷雾剂组(5 μg/吸)和粉吸入剂组发生急性加重风险相似[OR=1.01, 95%CI(0.94~1.09),P=0.71]。圣乔治呼吸问卷评分上,噻托溴铵喷雾剂组(5 μg/吸)优于安慰剂组[MD=-3.6, 95%CI(-3.88~-3.32),P<0.01]。噻托溴铵喷雾剂组(5 μg/吸)和粉吸入剂组在稳态时的最大血药浓度、血药浓度-时间曲线下面积均相似[MD=0.2, 95%CI(-5.1~5.5),P=0.94];MD=-1.01, 95%CI(-11.78~9.77),P=0.85]。安全性部分纳入9项RCT研究,噻托溴铵喷雾剂组(5 μg/吸)与安慰剂组及粉吸入剂组的不良反应发生率均相似[RR=0.95, 95%CI(0.89~1.00),P=0.05,OR=1.07, 95%CI(1.00~1.16),P=0.06]。 结论: 噻托溴铵喷雾剂与粉吸入剂具有相似的疗效,均能有效改善慢阻肺患者肺功能及临床症状,且安全性较好;但其远期疗效及安全性有待长期随访的RCT研究结果验证。.
引用
- Cai HD, Hou J, Lyu YN, et al. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review]. Zhonghua Jie He He Hu Xi Za Zhi. 2017. PMID: 28810313. doi:10.3760/cma.j.issn.1001-0939.2017.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。